Mystery Gunk Triggers Massive Drug Pull

Blurred store aisle with RECALL stamp overlay. — MASSIVE DRUG PULL

Nearly a million bottles of heart and kidney medication are being pulled from shelves — and nobody will tell you exactly what was found on the pills.

Story Snapshot

Amgen voluntarily recalled 944,142 bottles of Corlanor and Sensipar after a foreign substance was found on tablet surfaces in one lot.
The Food and Drug Administration (FDA) classified this as a Class II recall, meaning the chance of serious harm is remote and no illnesses have been reported.
The foreign matter sat on the tablets’ outer coating, not inside them — but Amgen has not said what the substance actually was.
Manufacturing practice violations were also reported, and Amgen has released no public explanation or corrective action plan.

What Triggered a Recall of Nearly One Million Bottles

Amgen pulled 944,142 bottles of two medications — Corlanor, used for heart failure, and Sensipar, used for kidney disease — after a quality check found something unexpected on a tablet’s surface.

The foreign substance was found on the outer coating of the pills, not within the tablets themselves. Hazard tests rated the risk to patients as low. No complaints, injuries, or illnesses have been reported in connection with the recalled products. ^[2]

Nearly 1 million bottles of heart and kidney medication recalled over foreign substance found on tablets https://t.co/jbYph6PBN6

— FOX Business (@FoxBusiness) June 28, 2026

Amgen acted on its own, without an FDA order. The recall covered all lots still within their expiration dates that passed through one specific packaging area — AML Building 23 — at Amgen’s facility.

The decision to expand the search beyond the single lot where the substance was found was a precautionary measure. ^[2]

That is standard practice in the drug industry. When a problem appears in one batch tied to a shared production space, companies pull everything from that space to be safe.

What Class II Actually Means — And Why the Headlines Got It Wrong

The FDA labeled this a Class II recall. That classification means the chance of serious health consequences is remote. ^[2] Most drug recalls fall into this category.

In fact, FDA data from 2012 through 2023 show that foreign material or particulates in drugs were among the top three reasons for recalls in 2023, especially in cardiovascular medications. ^[14]

This is not rare. It is one of the most common quality failures in pharmaceutical manufacturing. Social media posts urged people to “Check your medication ASAP” without explaining that the risk level was low. That kind of framing causes unnecessary panic and pharmacy runs that serve no one.

The Part of This Story Amgen Has Not Explained

Here is where the story gets harder to defend. Amgen has not told the public what the foreign substance was. No chemical identity. No description of whether it was a plastic fragment, a metal particle, or something else entirely. ^[3]

That silence is a problem. Alongside the contamination finding, regulators also documented deviations from Current Good Manufacturing Practice, the federal rules that govern how drugs must be made. ^[4]

Amgen has released neither a root cause analysis nor a corrective action plan. Voluntary recalls earn goodwill. Voluntary recalls without follow-up explanations erode it.

A company can do the right thing by pulling a product and still fail the transparency test. Amgen did the former. It has not yet done the latter. Patients taking Corlanor or Sensipar depend on these medications daily.

They deserve more than a recall notice with a blank where the explanation should be. The FDA’s job is to oversee the recall strategy — not to fill in the gaps Amgen leaves open. ^[14]

Until Amgen publishes its findings, the public is left guessing about what contaminated their pills and whether the factory-floor problem has actually been fixed.

What Patients Should Actually Do Right Now

If you take Corlanor or Sensipar, do not stop your medication without talking to your doctor first. Stopping a heart or kidney medication abruptly can cause serious harm — far more harm than the low-risk issue that triggered this recall.

Check the lot number on your bottle against the recall list posted on the FDA’s website. If your lot is affected, contact your pharmacy for a replacement or refund. ^[2] The medication risk here is low. The risk of stopping without medical guidance is not.